Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

Inclusion Criteria: PRE-STEM CELL TRANSPLANT (SCT) * Patients undergoing their first T cell replete allo-HCT for chronic lymphocytic leukemia (CLL), Hodgkin Lymphoma (HL), or the following subtypes of Non-Hodgkin lymphoma: Mantle cell lymphoma (MCL) and follicular center cell lymphoma (FL) * Meeting institutional criteria for allo-HCT. Ejection fraction by echocardiogram or MUGA \>40%, pulmonary function test with adjusted DLCO ≥ 60% * Matched (8/8) or mismatched (7/8) related, unrelated HCT * Stem cell source: bone marrow, peripheral blood stem cell * Disease criteria: Cohort A Chronic lymphocytic leukemia * Disease burden: lymph node size \< 5 cm and/or extra-nodal involvement \< 5 cm AND * 17 p deletion (detected by any assay) (\> or equal to 20% of cells involved if assay is conventional cytogenetics or fluorescence in situ hybridization \[FISH\]) or NOTCH mutation at any time point during disease course; patient should have received at least 1 line of therapy; prior ibrutinib therapy is permitted OR * Relapsed/refractory chronic lymphocytic leukemia \> or equal to 2 lines of therapy; prior ibrutinib therapy is permitted Mantle cell lymphoma * Disease burden: lymph node size \< 5 cm and/or extra-nodal involvement \< 5 cm AND * Relapsed/refractory mantle cell lymphoma \> or equal to 1 line of therapy. Prior ibrutinib therapy is permitted. Prior autologous hematopoietic cell transplant is permitted. OR * Mantle cell lymphoma blastoid variant in first complete respons…